65,437 trials
Atherosclerotic Cardiovascular Disease
Primary: Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI…
Epilepsy With Partial-onset Seizures
Primary: Change in Average Daily Frequency (ADF) of Electrographic Partial-onset Seizures From End-of-Baseline (EOB) Period Video-EEG to End-of-Maintenance (EOM) Period Video-EEG…
Ulcerative Colitis
Primary: Serum Golimumab Concentration (μg/ml) — 3.3; 2.4 ug/ml
Breast Cancer Stage IV · Unresectable Locally Advanced Invasive Breast Cancer · Metastatic Invasive Breast Cancer
Primary: Clinical Benefit Rate — 33 percentage of participants
Resectable Pancreatic Cancers
Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Caregiver · Malignant Head and Neck Neoplasm · Paranasal Sinus Squamous Cell Carcinoma
Primary: Number of Participants Noting Quite a Bit/Very Much Helpful to Survey Questions — 4; 6; 7; 6 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity AUC(0-∞) of Lasmiditan — 385; 829; 1990 nanogram*hour per milliliter…
Rotator Cuff Tear
Primary: Change of Pain During Activity From Baseline to 3 Months After Intervention — -1.4; -1.5; -3.0 units on a scale — p=0.35
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response…
Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia
Primary: Percentage of Patients we Are Able to Test and Initiate Treatment Within a 21 Day Period — 21 Participants
Type 2 Diabetes
Primary: Area Over Basal for Postprandial Glucose From 0 to 600min — 591; 220; 197 mg*/min/dL
Pulmonary Embolism
Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change
Elderly Study Participants · Adult Study Participants
Primary: The Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil (PSL) — 903.6; 838.4 ng/mL
Lymphoma
Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants